KFDA approves Hepsera for treatment of chronic hepatitis B

Published: 2004-02-26 06:57:00

Updated: 2004-02-26 06:57:00

GSK Korea said on February 19 that Hepsera (adefovir dipivoxil), an oral nucleotide analogue for the treatment of chronic hepatitis B, was approved by the Korea Food and Drug Administration.

The discovery of adefovir's potent inhibitory action on viral reverse transcriptase lead to exploratio...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK